ArticleCancers2021

TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study.

Alessandra Raimondi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.